Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/1078-0432.CCR-22-3549 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comprehensive Overview of Molecular, Imaging, and Therapeutic Challenges in Rectal Mucinous Adenocarcinoma.
Int J Mol Sci
January 2025
3rd Department of Surgery, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400162 Cluj-Napoca, Romania.
Rectal cancer is one of the most frequent malignancies worldwide. The most common histological type is adenocarcinoma, followed by mucinous adenocarcinoma. The outcome is less favorable for the mucinous type, yet the treatment course is the same.
View Article and Find Full Text PDFThe Immunohistochemical Prognostic Value of Nuclear and Cytoplasmic Silent Information Regulator 1 Protein Expression in Saudi Patients with Breast Cancer.
Biomolecules
January 2025
Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Background: The mammalian NAD-dependent deacetylase sirtuin-1 family (named also silent information regulator or SIRT family, where NAD stands for "nicotinamide adenine dinucleotide" (NAD)) appears to have a dual role in several human cancers by modulating cell proliferation and death. This study examines how SIRT1 protein levels correlate with clinicopathological characteristics and survival outcomes in patients with breast cancer.
Methods: A total of 407 BC formalin-fixed paraffin-embedded (FFPE) samples were collected from King Abdulaziz University Hospital, Saudi Arabia.
A Novel Nomogram for Estimating a High-Risk Result in the EndoPredict Test for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Carcinoma.
Cancers (Basel)
January 2025
Department of Pathology, Hospital Universitario La Paz, 28046 Madrid, Spain.
: The EndoPredict assay has been widely used in recent years to estimate the risk of distant recurrence and the absolute chemotherapy benefit for patients with estrogen (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. However, there are no well-defined criteria for selecting patients who may benefit from the test. The aim of this study was to develop a novel nomogram to estimate the probability of obtaining a high-risk EndoPredict result in clinical practice.
View Article and Find Full Text PDFHigh Frequency of Alterations in Ovarian Cancers: Clinicopathological and Molecular Associations.
Cancers (Basel)
January 2025
Department of Cancer Pathomorphology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Background: The phosphoinositide 3-kinase (PI3K) pathway is activated in multiple cancers. However, the significance of encoding the PI3K regulatory subunit, an inhibitor of the PI3K catalytic subunit encoded by , in ovarian cancer development is largely unknown.
Methods: Here, we investigated genomic alterations and gene expression by direct sequencing and qPCR methods in 197 ovarian cancers.
The Role of [F]FDG PET and Clinicopathologic Factors in Detecting and Predicting Bone Marrow Involvement in Non-Hodgkin Lymphoma.
Cancers (Basel)
January 2025
Department of Pathology, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.
: This study evaluates the diagnostic accuracy of [18F]fluorodeoxyglucose ([F]FDG) positron emission tomography (PET) using bone marrow biopsy (BMB) and clinical follow-up as reference standards. It further identifies predictive factors for bone marrow involvement (BMI) in non-Hodgkin lymphoma (NHL) patients. : NHL patients who underwent [F]FDG PET and BMB at diagnosis in a tertiary cancer center were included in this study.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!